Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
NuGen Medical Devices Inc. is a Canada-based medical device company focused on the development and commercialization of proprietary drug delivery technologies. The company operates within the medical devices and biopharmaceutical delivery industries, with a primary emphasis on improving the administration of injectable therapies. NuGen’s core value proposition centers on reducing patient discomfort and improving adherence through needle-free or minimally invasive delivery systems.
The company’s principal product is the InsuJet™ needle-free injection system, designed to deliver subcutaneous medications without the use of conventional needles. NuGen primarily targets patients requiring frequent injections, such as those with diabetes or chronic conditions requiring biologics. The company was founded in 2012 and has evolved from an early-stage technology developer into a commercialization-focused organization, securing regulatory clearances in multiple international markets. NuGen Medical Devices Inc. trades on the OTC Markets under the ticker NGMDF and is also listed on the Canadian Securities Exchange.
Business Operations
NuGen generates revenue primarily through the sale and distribution of its InsuJet™ device systems, including reusable injectors and disposable ampoules. Operations are centered on device commercialization, regulatory approvals, distribution agreements, and ongoing product refinement. The company does not manufacture pharmaceutical drugs itself but partners with distributors and healthcare providers to integrate its delivery system with existing injectable therapies.
The company’s operations are predominantly international, with limited direct commercial activity in the United States due to regulatory constraints. NuGen relies on third-party manufacturing, logistics providers, and regional distribution partners rather than vertically integrated production. Public disclosures indicate no material revenue diversification beyond the InsuJet™ platform, and there is no verified evidence of additional commercialized product lines as of the most recent filings. Data inconclusive based on available public sources regarding the scale of recurring revenue and long-term supply contracts.
Strategic Position & Investments
NuGen’s strategic direction focuses on expanding adoption of needle-free injection technology through regulatory approvals, distributor partnerships, and market education. Growth initiatives have emphasized penetration into markets with high insulin usage and demand for patient-friendly delivery alternatives. The company has stated intentions to pursue additional therapeutic applications for its technology, though timelines and investment levels are not consistently disclosed across public sources.
There is no verified record of major acquisitions or controlling interests in other operating companies. NuGen does not report a diversified investment portfolio, and its strategy appears concentrated on organic growth of the InsuJet™ platform. Public filings and investor disclosures reference ongoing evaluation of next-generation delivery technologies, but specific emerging technologies or funded R&D programs beyond incremental product improvements cannot be independently confirmed.
Geographic Footprint
NuGen Medical Devices Inc. is headquartered in Canada, with its corporate offices located in Toronto, Ontario. The company’s commercial presence is primarily international, with regulatory approvals and distribution activities in parts of Europe, Asia, Latin America, and the Middle East. These regions represent the majority of the company’s reported commercial focus.
The company does not maintain a broad physical office footprint outside Canada and operates largely through regional distributors and partners. Market presence varies significantly by country, depending on local regulatory approvals and reimbursement frameworks. Data inconclusive based on available public sources regarding the relative revenue contribution by region.
Leadership & Governance
NuGen Medical Devices Inc. is led by a management team with experience in medical devices, healthcare commercialization, and public company governance. The company was founded by Joseph W. Reynolds, who has played a central role in shaping its product and commercialization strategy. Leadership has emphasized patient-centric innovation and regulatory-driven market expansion.
Key executives include:
- Joseph W. Reynolds – Founder, President, and Chief Executive Officer
- David Perez – Chief Financial Officer
- Chris Richardson – Director
- J. Joseph Kirsner – Director
The company is governed by a board of directors responsible for strategic oversight, regulatory compliance, and capital allocation. Management’s stated vision focuses on expanding access to needle-free injection solutions while maintaining capital discipline.